Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cisplatin + Paclitaxel + Toripalimab-tpzi |
Indication/Tumor Type | esophagus squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Cisplatin + Paclitaxel + Toripalimab-tpzi | Phase III | Actionable | In a post hoc analysis of a Phase III trial (JUPITER-06), addition of Loqtorz (toripalimab-tpzi) to paclitaxel and cisplatin improved progression-free survival (5.7 vs 5.5 mo, HR 0.59, p=0.0005 TPS H; 6.1 vs 5.7 mo, HR 0.59, p=0.0089 TPS L) and median overall survival (16.9 vs 10.8 mo, HR=0.61, p=0.0133 TPS H; not reached vs 11.6 mo, HR=0.63, p=0.0913 TPS L) in patients with esophagus squamous cell carcinoma with low (L, TPS<1%) or high (H, TPS>=1%) CD274 (PD-L1) expression (PMID: 36473145). | 36473145 |
PubMed Id | Reference Title | Details |
---|---|---|
(36473145) | Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. | Full reference... |